XML 99 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Reportable Segments
 12 Months Ended
Jul. 31, 2020
Segment Reporting [Abstract]  
Reportable Segments Reportable Segments
 
In accordance with ASC Topic 280, “Segment Reporting,” (“ASC 280”), we have determined our reportable business segments based upon an assessment of product types, organizational structure, customers and internally prepared financial statements. The primary factors used by us in analyzing segment performance are net sales and income from operations. In the first quarter of fiscal 2020 and as a result of the Hu-Friedy acquisition, we moved the financial reporting and management of our industrial biological and chemical indicator business to our Dental segment from our Life Sciences segment. Prior year segment disclosures have been recast to conform to the current year presentation.

None of our customers accounted for 10% or more of our consolidated net sales during fiscal 2020, 2019 and 2018.

Our reportable segments are as follows:
 
Medical: designs, develops, manufactures, sells and installs a comprehensive offering of products and services comprising a complete circle of infection prevention solutions. Our products include endoscope reprocessing and endoscopy procedure products.
 
Life Sciences: designs, develops, manufactures, sells, and installs water purification systems for medical, pharmaceutical and other bacteria controlled applications. We also provide filtration/separation and disinfectant technologies to the medical and life science markets through a worldwide distributor network. Two customers collectively accounted for approximately 41.7%, 40.2% and 48.0% of our Life Sciences segment net sales in fiscal 2020, 2019 and 2018, respectively.
 
Dental: designs, manufactures, sells, supplies and distributes a broad selection of products used by the global dental profession comprising a complete circle of protection. Our products include hand and powered dental instruments, infection control products, personal protective equipment (PPE) and water quality products for the dental suite. Three customers collectively accounted for approximately 42.0%, 47.6% and 45.1% of our Dental segment net sales in fiscal 2020, 2019 and 2018, respectively.

Dialysis: designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers (a device serving as an artificial kidney), as well as dialysate concentrates and supplies utilized for renal dialysis. Two customers collectively
accounted for approximately 41.0%, 41.0% and 40.6% of our Dialysis segment net sales in fiscal 2020, 2019 and 2018, respectively. One these customers is the same customer noted above under our Life Sciences segment.
 
Information as to reportable segments is summarized below:
 Year Ended July 31,
 202020192018
Net sales:   
Medical$468,078 $523,669 $473,937 
Life Sciences (1)
195,410 194,950 211,210 
Dental (1)
322,398 167,680 155,180 
Dialysis30,162 31,856 31,595 
Total$1,016,048 $918,155 $871,922 
_______________________________________________
(1)In fiscal 2019 and fiscal 2018, approximately $6,072 and $5,820, respectively, of net sales were reclassified out of our Life Sciences segment and into our Dental segment associated with the changes in our segments noted above.

 Year Ended July 31,
 202020192018
Income from operations:   
Medical$56,065 $98,356 $86,833 
Life Sciences (1)
26,904 17,528 35,100 
Dental (1)
3,378 25,313 31,707 
Dialysis7,480 4,922 7,380 
 93,827 146,119 161,020 
General corporate expenses45,520 62,600 39,356 
Income from operations48,307 83,519 121,664 
Interest expense, net41,355 9,505 5,289 
Other income— (1,305)(1,138)
Income before income taxes$6,952 $75,319 $117,513 
_______________________________________________
(1)In fiscal 2019 and 2018, approximately $3,024 and $1,703 of income from operations were reclassified out of our Life Sciences segment and into our Dental segment associated with the changes in our segments noted above.

 July 31,
 20202019
Identifiable assets:  
Medical$549,194 $532,250 
Life Sciences157,115 184,737 
Dental1,037,947 272,309 
Dialysis19,114 19,016 
General corporate, including cash and cash equivalents308,384 62,054 
Total$2,071,754 $1,070,366 
 
 Year Ended July 31,
 202020192018
Capital expenditures:   
Medical$15,587 $52,907 $18,996 
Life Sciences2,134 16,408 4,409 
Dental15,304 16,243 2,441 
Dialysis771 3,203 644 
General corporate— 6,677 11,208 
Total$33,796 95,438 37,698 
 Year Ended July 31,
 202020192018
Depreciation and amortization:   
Medical$24,133 $23,033 $19,002 
Life Sciences6,856 7,482 5,628 
Dental29,702 9,844 8,756 
Dialysis44 39 711 
General corporate2,667 1,961 733 
Total$63,402 $42,359 $34,830 
 
Information as to geographic areas (including net sales which represent the geographic area from which we derive its net sales from external customers) is summarized below:
 Year Ended July 31,
 202020192018
Net sales:   
United States$742,410 $665,661 $643,744 
Europe/Africa/Middle East167,360 148,334 131,130 
Asia/Pacific73,517 66,228 57,108 
Canada27,417 32,152 33,524 
Latin America/South America5,344 5,780 6,416 
Total$1,016,048 $918,155 $871,922 
 
 July 31, 
 20202019
Total long-lived assets:  
United States$211,701 $128,010 
Europe/Africa/Middle East60,752 64,742 
Asia/Pacific7,478 4,201 
Canada4,993 1,995 
Total284,924 198,948 
Goodwill and intangible assets, net1,140,204 519,622 
Total$1,425,128 $718,570